Biologic & Biosimilar RA Drugs Global Market Report 2023

Biologic & Biosimilar RA Drugs Global Market Report 2024 – By Source (Microbial, Mammalian, Other Sources), By Disease (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases), By Manufacturing (Outsourced, In-House), By Mode Of Purchase (Prescription Drugs, Over-The-Counter (OTC) Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Biologic & Biosimilar RA Drugs Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Biologic & Biosimilar RA Drugs Market Definition And Segments

Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis.

The main sources of biologic & biosimilar RA drugs are microbial, mammalian, and others. Microbial sources refer to sources such as bacteria, yeast, and fungi. The various diseases involved are oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others whose drugs are manufactured by outsourced and in-house. They are sold by prescription drugs, and over-the-counter (OTC) drugs in hospital pharmacies, retail pharmacies, and online pharmacies.

The biologic & biosimilar RA drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases

3) By Manufacturing: Outsourced, In-House

4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The biologic & biosimilar RA drugs market size has grown strongly in recent years. It will grow from $13.44 billion in 2023 to $14.15 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies.

The biologic & biosimilar RA drugs market size is expected to see strong growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare.

Growing Geriatric Population And Rising Rheumatoid Arthritis Cases Propel Biologics And Biosimilar Ra Drugs Market

The rising older population and increasing incidence of rheumatoid arthritis are driving the biologics and biosimilar RA drugs market forward. The older population refers to people who are aged 60 years or older. Rheumatoid arthritis is an autoimmune disease in which the immune system of a person attacks its healthy cells, and the joints of the person are affected. Rheumatoid arthritis is most likely to affect people in old age as the immune system gets weaker with old age. Biologics and biosimilar RA drugs are very useful for the treatment of rheumatoid arthritis as compared to conventional drugs. For instance, according to the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, there were about 1 billion people aged 60 and above in the world in 2020 and this population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, according to the Centers for Disease Control and Prevention, a US-based governmental public health agency, the number of adults suffering from arthritis in the USA is expected to increase to 78.4 million by 2040 while 34.6 million people may suffer from arthritis-related activity limitations. Therefore, the increasing geriatric population along with the increasing RA cases is driving the biologics and biosimilars RA drugs market forward.

Increasing Healthcare Spending Is Anticipated To Fuel The Biologic & Biosimilar Ra Drugs Market

The increasing healthcare spending is expected to propel the growth of the biologic & biosimilar RA drug market going forward. Healthcare spending refers to the total monetary investment made by individuals, governments, and organizations in medical goods and services, encompassing expenses related to the prevention, treatment, and management of health conditions. The use of biologic and biosimilar RA drugs optimizes rheumatoid arthritis management, balancing efficacy, and cost-effectiveness in the provision of specialized and often expensive treatments required in healthcare spending. For instance, in November 2023, according to the CIHI, a Canada-based Institute for Health Information health company, the total health spending in Canada is expected to reach $344 billion in 2023, or $8,740 per Canadian, which is a 2.8% in 2023, after a mere 1.5% growth in 2022. Therefore, the increasing healthcare spending is driving the biologic & biosimilar RA drug market.

Major companies operating in the biologic & biosimilar RA drugs market report are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline PLC, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc. .

Biosimilar Treatment To Provide An Affordable Alternative

New innovations are a key trend in gaining popularity in the biologic & biosimilar RA drugs market. Major companies operating in the biologic & biosimilar RA drugs market are focused on developing biosimilar treatments such as Dual Concentration Biosimilar Options to provide an affordable alternative. For instance, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. Available in high and low concentrations, HADLIMA aims to enhance access and affordability for patients with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, contributing to expanded patient access. HADLIMA includes an autoinjector, recognized by the Arthritis Foundation, and a patient support program, HADLIMA For You, offering educational resources and co-pay support. It is indicated for various conditions, including rheumatoid arthritis and Crohn's disease. HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), providing patients with seamless continuity of care.

Innovative Biologics For Polymyalgia Rheumatica Treatment

Major companies operating in the biologic & biosimilar RA drugs market receiving approval for innovative biologics such as injectable medication to expand its offerings for polymyalgia rheumatica treatment. An injectable medication refers to a substance, often in liquid form, that is administered into the body using a needle and syringe. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based Biotechnology company, and Sanofi, a France-based healthcare and pharmaceutical company received FDA approval for Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adults who have an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. The approval is based on positive results from the SAPHYR Phase 3 trial, where Kevzara showed a significant 28% sustained remission rate compared to 10% for placebo at 52 weeks. Kevzara, initially approved for rheumatoid arthritis, becomes the first and only biologic treatment for PMR, offering relief from the debilitating symptoms.

Biocon Expands Biologics Portfolio With Acquisition Of Viatris' Global Biosimilars Business

In November 2022, Biocon, an India-based biopharmaceutical company acquired Viatris’ global biosimilars business for $3 billion. The acquisition brings patients, consumers, and payors closer to Biocon Biologics by giving it direct commercial capabilities and supporting infrastructure in numerous emerging markets as well as advanced markets. Viatris is a US-based pharmaceutical company manufacturing biosimilars for the treatment of rheumatoid arthritis along with other diseases.

North America was the largest region in the biologic & biosimilar RA drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biologic & biosimilar RA drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biologics and biosimilars RA drugs market consists of sales of branded and generic biologics and biosimilar RA drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The biologic & biosimilar RA drugs market research report is one of a series of new reports from The Business Research Company that provides biologic & biosimilar RA drugs market statistics, including biologic & biosimilar RA drugs industry global market size, regional shares, competitors with biologic & biosimilar RA drugs market share, detailed biologic & biosimilar RA drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the biologic & biosimilar RA drugs industry. This biologic & biosimilar RA drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Biologic & Biosimilar RA Drugs Market Characteristics

    3. Biologic & Biosimilar RA Drugs Market Trends And Strategies

    4. Biologic & Biosimilar RA Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Biologic & Biosimilar RA Drugs Market Size and Growth

    5.1. Global Biologic & Biosimilar RA Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Biologic & Biosimilar RA Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Biologic & Biosimilar RA Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Biologic & Biosimilar RA Drugs Market Segmentation

    6.1. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Microbial

    Mammalian

    Other Sources

    6.2. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oncology

    Immunological Disorders

    Cardiovascular Disorders

    Hematological Disorders

    Other Diseases

    6.3. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Outsourced

    In-House

    6.4. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Prescription Drugs

    Over-The-Counter (OTC) Drugs

    6.5. Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Online Pharmacies

    7. Biologic & Biosimilar RA Drugs Market Regional And Country Analysis

    7.1. Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Biologic & Biosimilar RA Drugs Market  

    8.1. Asia-Pacific Biologic & Biosimilar RA Drugs Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Biologic & Biosimilar RA Drugs Market  

    9.1. China Biologic & Biosimilar RA Drugs Market Overview  

    9.2. China Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Biologic & Biosimilar RA Drugs Market  

    10.1. India Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Biologic & Biosimilar RA Drugs Market  

    11.1. Japan Biologic & Biosimilar RA Drugs Market Overview  

    11.2. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Biologic & Biosimilar RA Drugs Market  

    12.1. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Biologic & Biosimilar RA Drugs Market  

    13.1. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Biologic & Biosimilar RA Drugs Market  

    14.1. South Korea Biologic & Biosimilar RA Drugs Market Overview  

    14.2. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Biologic & Biosimilar RA Drugs Market  

    15.1. Western Europe Biologic & Biosimilar RA Drugs Market Overview

    15.2. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Biologic & Biosimilar RA Drugs Market  

    16.1. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Biologic & Biosimilar RA Drugs Market  

    17.1. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Biologic & Biosimilar RA Drugs Market  

    18.5. France Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Biologic & Biosimilar RA Drugs Market  

    19.9. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Biologic & Biosimilar RA Drugs Market  

    20.13. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Biologic & Biosimilar RA Drugs Market  

    21.1. Eastern Europe Biologic & Biosimilar RA Drugs Market Overview

    21.2. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Biologic & Biosimilar RA Drugs Market  

    22.1. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Biologic & Biosimilar RA Drugs Market  

    23.1. North America Biologic & Biosimilar RA Drugs Market Overview

    23.2. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Biologic & Biosimilar RA Drugs Market  

    24.1. USA Biologic & Biosimilar RA Drugs Market Overview

    24.2. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Biologic & Biosimilar RA Drugs Market  

    25.1. Canada Biologic & Biosimilar RA Drugs Market Overview

    25.2. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Biologic & Biosimilar RA Drugs Market  

    26.1. South America Biologic & Biosimilar RA Drugs Market Overview

    26.2. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Biologic & Biosimilar RA Drugs Market  

    27.1. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Biologic & Biosimilar RA Drugs Market  

    28.1. Middle East Biologic & Biosimilar RA Drugs Market Overview

    28.2. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Biologic & Biosimilar RA Drugs Market  

    29.1. Africa Biologic & Biosimilar RA Drugs Market Overview

    29.2. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Biologic & Biosimilar RA Drugs Market Competitive Landscape And Company Profiles

    30.1. Biologic & Biosimilar RA Drugs Market Competitive Landscape

    30.2. Biologic & Biosimilar RA Drugs Market Company Profiles

    30.2.1. Samsung BioLogics Co. Ltd.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Amgen Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novo Nordisk A/S

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. AbbVie Inc.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Johnson & Johnson Services Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Biologic & Biosimilar RA Drugs Market Competitive Benchmarking

    32. Global Biologic & Biosimilar RA Drugs Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Biologic & Biosimilar RA Drugs Market

    34. Biologic & Biosimilar RA Drugs Market Future Outlook and Potential Analysis

    34.1 Biologic & Biosimilar RA Drugs Market In 2028 - Countries Offering Most New Opportunities

    34.2 Biologic & Biosimilar RA Drugs Market In 2028 - Segments Offering Most New Opportunities

    34.3 Biologic & Biosimilar RA Drugs Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 75: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 76: Samsung BioLogics Co. Ltd. Financial Performance
  • Table 77: Amgen Inc. Financial Performance
  • Table 78: Novo Nordisk A/S Financial Performance
  • Table 79: AbbVie Inc. Financial Performance
  • Table 80: Johnson & Johnson Services Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Global Biologic & Biosimilar RA Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Global Biologic & Biosimilar RA Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: Asia-Pacific, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: China, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: India, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Japan, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Australia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: Indonesia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: South Korea, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: Western Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: UK, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: Germany, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: France, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Italy, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Spain, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Eastern Europe, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: Russia, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: North America, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: USA, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: Canada, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: South America, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Brazil, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Middle East, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Source, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 75: Africa, Biologic & Biosimilar RA Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 76: Samsung BioLogics Co. Ltd. Financial Performance
  • Figure 77: Amgen Inc. Financial Performance
  • Figure 78: Novo Nordisk A/S Financial Performance
  • Figure 79: AbbVie Inc. Financial Performance
  • Figure 80: Johnson & Johnson Services Inc Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the biologic and biosimilar RA drugs market?

Biologics and biosimilars refer to a class of drugs that are extracted from living organisms such as living cells, microorganisms, and other living creatures. Biosimilars are biologics that have similar characteristics to an already approved biological molecule. These drugs are used for the treatment of rheumatoid arthritis. For further insights on the biologic and biosimilar RA drugs market, request a sample here

How will the biologic and biosimilar RA drugs market drivers and restraints affect the biologic and biosimilar RA drugs market dynamics? What forces will shape the biologic and biosimilar RA drugs industry going forward?

The biologic and biosimilar RA drugs market growth is aided by the increasing geriatric population along with the increasing RA cases. For further insights on the biologic and biosimilar RA drugs market, request a sample here

What is the forecast market size or the forecast market value of the biologic and biosimilar RA drugs market?

The biologic and biosimilar RA drugs market is expected to reach $15.19 billion in 2027 at a rate of 4.7%. For further insights on the biologic and biosimilar RA drugs market, request a sample here

How is the biologic and biosimilar RA drugs market segmented?

The global biologic and biosimilar RA drugs market is segmented as
1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
For further insights on the biologic and biosimilar RA drugs market,
request a sample here

Which region has the largest share of the biologic and biosimilar RA drugs market? What are the largest region's market size and growth rate?

North America was the largest region in the biologic and biosimilar RA drugs market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the biologic and biosimilar RA drugs market?

Key competitors in the biologic and biosimilar RA drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Sanofi Pasteur, Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc.. For further insights on the biologic and biosimilar RA drugs market, request a sample here.

What are the key trends in the biologic and biosimilar RA drugs market?

Major trends influencing the biologic and biosimilar RA drugs market include product innovations. Major companies in the biologics and biosimilars RA drugs market are introducing innovative products to sustain their position in the market. For further insights on the biologic and biosimilar RA drugs market, request a sample here.

What are the major opportunities in the biologic and biosimilar RA drugs market? What are the strategies for the biologic and biosimilar RA drugs market?

For detailed insights on the major opportunities and strategies in the biologic and biosimilar RA drugs market, request a sample here.

How does the biologic and biosimilar RA drugs market relate to the overall economy and other similar markets?

For detailed insights on biologic and biosimilar RA drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the biologic and biosimilar RA drugs industry?

For detailed insights on the mergers and acquisitions in the biologic and biosimilar RA drugs industry, request a sample here.

What are the key dynamics influencing the biologic and biosimilar RA drugs market growth? SWOT analysis of the biologic and biosimilar RA drugs market.

For detailed insights on the key dynamics influencing the biologic and biosimilar RA drugs market growth and SWOT analysis of the biologic and biosimilar RA drugs industry, request a sample here.